“• As a priority, all adults, adolescents and children with CHB and clinical
evidence of compensated or decompensated cirrhosis (or cirrhosis based on
APRI score >2 in adults) should be treated, regardless of ALT levels, HBeAg
status or HBV DNA levels. (Strong recommendation, moderate quality of
evidence)
• Treatment is recommended for adults with CHB who do not have clinical evidence
of cirrhosis (or based on APRI score ≤2 in adults), but are aged more than 30 years
(in particular), and have persistently abnormal ALT levels and evidence of high-
level HBV replication (HBV DNA >20 000 IU/mL), regardless of HBeAg status.
(Strong recommendation, moderate quality of evidence)”
